TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Spatial resolution of MRI imaging sequences
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Intra-operative Blood Loss
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: subjective sleepiness and other OSAS symptoms
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: Oxygen levels in tissues
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Serum CTX
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Number of Participants Reaching Two or More Cardiometabolic Risk Goals
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Serum interleukin-6 (IL-6)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Serum soluble interleukin-6 receptor (sIL-6R)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Freedom From MACE Within 30 Days Post-procedure
Endpoint domain: Mortality/survival
Primary endpoint: Procedural Success
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Incidence Rates of Overall Malignancies
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Incidence Rates of Melanoma
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Incidence Rates of Non-melanoma Skin Cancer
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Incidence Rates of Basal Cell Carcinoma
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Incidence Rates of Squamous Cell Carcinoma
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Vaginal Health Index (VHI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Visual Analogue Scale (VAS) for vaginal dryness
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: SF 12 questionnaire
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Time in the Glycaemic Target Range (5.5-7.0 mmol/l)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in extravascular lung water index (EVLWi)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: FMRT resting state connectivity of the default mode network
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sensitivity/Specificity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Diagnostic odds ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion achieving remission on HRSD-24
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Subjects With Anti-polyribosyl-ribitol-phosphate (Anti-PRP) Antibody Concentration Equal to or Above (≥) Cut-off Value
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Concentration of Antibodies Against Streptococcus Pneumoniae Serotypes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Number of Subjects Reporting Any Grade 3 Symptoms
Endpoint domain: Adverse events/effects
Primary endpoint: Wheelchair skills test - power mobility version
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Recurrence Score variation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Percentage of patients experiencing at least one Hypoglycaemic Event
Endpoint domain: Adverse events/effects
Primary endpoint: Participant Retention
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Intervention Reach
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Change in perceived intimacy scores
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: severe GVHD
Endpoint domain: Adverse events/effects
Primary endpoint: Frailty Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: number of related AEs grade 3 or >
Endpoint domain: Adverse events/effects
Primary endpoint: change in composite neuropsychological score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Axillary recurrence
Endpoint domain: Mortality/survival
Primary endpoint: Cerebral vasospasm-related morbidity and mortality
Endpoint domain: Mortality/survival
Primary endpoint: Improvement of sleep
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: Patient satisfaction with the consultation
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Change in peak nasal inspiratory flow
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: General task performance (response time of the random sequence)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Implicit sequence learning (difference in response time between the random and repeated sequences)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Inferior Corneal Staining (ICS) Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to Clinically Significant Progression of Cardiac Disease
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Time to Clinically Significant Progression of Cerebrovascular Disease
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Total length of desaturation episodes (ToLDE) time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time of onset of Rocuronium action
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time at which maximal suppression occurs
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reversal of Rocuronium
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pharmacokinetic Parameters
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Tremor reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Number of Participants With 1 or More Adverse Events (AEs) or Any Serious AEs
Endpoint domain: Adverse events/effects
Primary endpoint: Induration Size
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: DWM Hyperintensity Value >2 in Subjects Who Received Acute Treatment for Mania
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: DWM Hyperintensity Value >2 in Subjects Who Received Continuation Treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Somatosensory phenotype detected by quantitative sensory testing (QST)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change of neuropathic pain detected by DN4 questionnaire
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in Ryodoraku value
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Heart rate viability
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Maximum observed plasma peak concentration (Cmax) of midazolam
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area under plasma concentration-time curve from time zero to infinity (AUCinf) of midazolam
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Half-life (t1/2) of midazolam
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: detectable hip cartilage damage
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Peak Plantar Pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sensitivity of parametric FES-PET/CT
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Score on Barry-Albright Dystonia Scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Score on Patient Global Impression of Improvement at End of Study
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: haematological response rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Assessment of muscle activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sensory evaluation - monofilaments
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Impact on blood pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Impact on lipid profile
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Expiratory time
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Inspiratory Capacity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Patients' adherence to registering for medically certified cannabis
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Patients' adherence to procuring medically certified cannabis
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Anatomical stability of aneurysm treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Retreatment rate
Endpoint domain: Adverse events/effects
Primary endpoint: Differences in cardiac output
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Number of Participants Experiencing Clinical Failure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Vasoconstriction Index (VI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Enrollment and retention rates
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: PTSD diagnosis (current CAPS dx)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: PTSD threshold (PCL derived screening estimate)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Neuropsych performance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants With Confirmed Treatment Area Closure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Actual Expansion Ratios
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Rate of adherence to drug prescription
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Number of Combined Active Lesions (CAL)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Rate of in vivo adipogenesis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Fluid Balance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area Under the Plasma Concentration-Time Curve (AUC) From Dosing to Infinity (AUC0-∞) of Sugammadex
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Participants With ≥1 Adverse Event (AE)
Endpoint domain: Adverse events/effects
Primary endpoint: Time to Recovery of Participant Train-of-Four (TOF) Ratio to ≥0.9
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sagittal balance of the spine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in the diversity of the gut microbiome
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of the sample deemed viable
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Impaired psoas muscle passivity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Number of subjects absent from work more than 10 days
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Timed-Up and Go-test for mobility evaluation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Frequency of Epistaxis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Duration of Epistaxis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Severity of Epistaxis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change From Baseline in the Hamilton Depression Rating Scale (HAMD17)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Number of Participants With Suicidal Behavior and Suicidal Ideation Subscales of the Columbia Suicide Severity Rating Scale (C-SSRS)
Endpoint domain: Adverse events/effects
Primary endpoint: Mean of Change From Baseline in Systolic and Diastolic Blood Pressure (BP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Angiographic NLG
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: High-density Lipoprotein Cholesterol
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Number of Participants With One or More Serious Adverse Event(s)
Endpoint domain: Adverse events/effects
Primary endpoint: Proportion of Participants With ACR 20 Response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total amount of pre-stored insulin secreted
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Diagnosis of proximal tubal occlusion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Size of large local reactions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Overall Response Rate (Complete and Partial Response)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Fat absorption inhibition
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Required dose of opioid to counteract nociceptive stimulation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in COVID-19 severity status
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: HIV-associated sexual behaviors
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: incident STDs
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: nonfatal cardiac arrest
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: re-operation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Peak oxygen reserve index value
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum Observed Plasma Concentration (Cmax) of Risdiplam
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to Maximum Plasma Concentration (Tmax) of Risdiplam
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Participants with Adverse Events (AEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Quality of Life Perception
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Portion of Drug Responders
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Change in average lower extremity spasticity score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neurological outcomes
Primary endpoint: Changing of diameter of colon
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Change in Barthel Index Score
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Mean Day 5 CD34+ Cells/kg Yield
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Percentage Change in Colorectal ACF
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Area under curve (AUC) of clinical attachment level (CAL) gain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Extent of linear bone growth (LBG)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of bone fill (%BF)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence and Severity of Acute Graft-vs-host Disease (GVHD)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Time to Engraftment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Accuracy of lymph node biopsy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Voice quality change
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Social Skills Improvement System Rating Scales - Parent
Endpoint domain: Life impact
Endpoint subdomain: Social functioning
Primary endpoint: Change in Social Skills Improvement System Rating Scales - Child
Endpoint domain: Life impact
Endpoint subdomain: Social functioning
Primary endpoint: Quantification of antibiotic resistance genes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Patients With an Objective Disease Progression Event
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Rest Myocardial Blood Flow (MBF)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Stress Myocardial Blood Flow (MBF)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Myocardial Blood Flow Reserve (MBFR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Vein Occlusion Rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Reflux-free Rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Time to local tumor progression
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Cardiac Death and Myocardial Infarction Composite Endpoint
Endpoint domain: Mortality/survival
Primary endpoint: Total urinary arsenic
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Mean Interlukin-6 Levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Proportion of Children Under 5 Years in Vulnerable Households That Have a Birth Certificate
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Proportion of Children Under 5 Years in Vulnerable Households That Have Up-to-date Vaccinations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Proportion of Children Aged 6-12 Years That Attended Primary School 80% of Days in the Last Month
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Number of Participants With Dose-Limiting Toxicities (DLTs)
Endpoint domain: Adverse events/effects
Primary endpoint: Proportion of patients prescribed inhaled corticosteroids
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Number of Participants With Treatment-Related Adverse Events (TRAEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants With Confirmed Best Overall Response (BOR)
Endpoint domain: Adverse events/effects
Primary endpoint: Glial fibrillary acid protein levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Efficacy of Ledipasvir-Sofosbuvir in treating chronic HCV infection
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sustained Virological Response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in marijuana use from baseline through end of intervention
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Composite of ischemic stroke & Non-CNS systemic embolism
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Symptomatic or Asymptomatic AT documented by ECG
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Number of Participants Meeting Patient-Caregiver Session and Care Plan Acceptability Criteria
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Rate of seroconversion to influenza vaccine
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Development of nausea and vomiting
Endpoint domain: Adverse events/effects
Primary endpoint: Insulin use
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Pharmacokinetics (PK) of AZD1656
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Absence of Residual Muscle Invasive Cancer
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Percentage of Dose-limiting Toxicities
Endpoint domain: Adverse events/effects
Primary endpoint: Duration of antibiotic therapy for the first episode of infection
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Total antibiotic exposure days per 1,000 days
Endpoint domain: Resource use
Endpoint subdomain: Other resource use